Pictet Asset Management Holding SA Buys 196,242 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Pictet Asset Management Holding SA raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 7.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,685,896 shares of the medical research company's stock after acquiring an additional 196,242 shares during the period. Thermo Fisher Scientific makes up 1.5% of Pictet Asset Management Holding SA's holdings, making the stock its 6th biggest holding. Pictet Asset Management Holding SA owned approximately 0.70% of Thermo Fisher Scientific worth $1,397,284,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Nomura Asset Management Co. Ltd. boosted its holdings in Thermo Fisher Scientific by 7.3% during the 4th quarter. Nomura Asset Management Co. Ltd. now owns 314,069 shares of the medical research company's stock valued at $163,388,000 after acquiring an additional 21,403 shares during the period. Broadway Wealth Solutions Inc. purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $287,000. New Age Alpha Advisors LLC purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $48,000. Providence Capital Advisors LLC lifted its holdings in Thermo Fisher Scientific by 1.0% during the 4th quarter. Providence Capital Advisors LLC now owns 13,886 shares of the medical research company's stock worth $7,224,000 after buying an additional 134 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $3,149,754,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock traded down $7.37 during trading hours on Tuesday, hitting $490.23. 707,954 shares of the company were exchanged, compared to its average volume of 1,915,481. The business has a 50-day moving average of $540.37 and a 200-day moving average of $551.02. Thermo Fisher Scientific Inc. has a 1 year low of $484.27 and a 1 year high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $184.94 billion, a price-to-earnings ratio of 29.66, a P/E/G ratio of 2.99 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, March 14th. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.35%. Thermo Fisher Scientific's payout ratio is 10.41%.

Wall Street Analyst Weigh In

Several research analysts recently commented on TMO shares. Raymond James reissued an "outperform" rating and set a $667.00 target price (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 target price on the stock in a report on Friday, January 10th. StockNews.com upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, January 14th. Morgan Stanley lifted their price objective on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. Finally, Wells Fargo & Company increased their target price on Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an "overweight" rating in a report on Friday, January 31st. Four investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $653.23.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CFO Stephen Williamson sold 9,825 shares of the business's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares of the company's stock, valued at $15,984,264.64. The trade was a 26.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael A. Boxer sold 3,775 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares in the company, valued at $5,759,736.32. This trade represents a 25.87 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.